Science Translational Medicine · 2024 · 27 citations · 66 references
Veterinary MedicineImmunologyPathobiologyHost-pathogen InteractionsInnate ImmunitySepsisBiomarkers In SepsisBone Morphogenetic Protein SignalingCytokine BiologyMacrophage BiologySepsis PathophysiologySepsis Prognosis28-Day MortalityBiomarker-based Sepsis DiagnosisBiomarker-based Sepsis PrognosticationBone Morphogenetic Protein ReceptorsHost Response BiomarkersHost-directed TherapyMurine ModelsTransforming Growth Factor-beta Signaling
Defining next-generation immune therapeutics for the treatment of sepsis will involve biomarker-based therapeutic decision-making. Bone morphogenetic protein 9 (BMP9) is a cytokine in the transforming growth factor-β superfamily. Here, circulating BMP9 concentrations were quantified in two independent cohorts of patients with sepsis. Decreased concentrations of serum BMP9 were observed in the patients with sepsis at the time of admission as compared with healthy controls. Concentrations of BMP9 at the time of admission were also associated with 28-day mortality, because patients with sepsis at a higher risk of death had lower BMP9 concentrations. The mechanism driving the contribution of BMP9 to host immunity was further investigated using in vivo murine sepsis models and in vitro cell models. We found that BMP9 treatment improved outcome in mice with experimental sepsis. BMP9-treated mice exhibited increased macrophage influx into the peritoneal cavity and more efficient bacterial clearance than untreated mice. In vitro, BMP9 promoted macrophage recruitment, phagocytosis, and subsequent bacterial killing. We further found that deletion of the type 1 BMP receptor ALK1 in macrophages abolished BMP9-mediated protection against polymicrobial sepsis in vivo. Further experiments indicated that the regulation of macrophage activation by the BMP9-ALK1 axis was mainly mediated through the suppressor of mother against decapentaplegic 1/5 signaling pathway. Together, these results suggest that BMP9 can both serve as a biomarker for patient stratification with an independent prognostic value and be developed as a host-directed therapy for sepsis.
66
Immunodesign of experimental sepsis by cecal ligation and puncture
Daniel Rittirsch, Markus Huber‐Lang, Michael A. Flierl et al. · Nature Protocols · 2008 · 2.2K citations · Full text
Kevin S Ikuta, Lucien R Swetschinski, Gisela Robles Aguilar et al. · The Lancet · 2022 · 2.1K citations · Full text
Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
Jonathan Boomer, Kathleen To, Kathy Chang et al. · JAMA · 2011 · 1.7K citations · Full text